Salvage immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combination therapy for metastatic renal cell carcinoma (mRCC).

Anish B Parikh,Sarah P. Psutka,Yuanquan Yang,Katharine Collier,Abdul Miah,Mingjia Li,Sherry Mori-Vogt,Megan Hinkley,Delaney Orcutt,Elliott Trott,Evan Gross,Duncan Hussey,Joel Kramer,Kaylee Oliva,Amir Mortazavi,Paul Monk,Edmund Folefac,Steven K. Clinton,Ming Yin

Salvage immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combination therapy for metastatic renal cell carcinoma (mRCC).

2021

Anish B Parikh
Sarah P. Psutka
Yuanquan Yang
Katharine Collier
Abdul Miah
Mingjia Li
Sherry Mori-Vogt
Megan Hinkley
Delaney Orcutt
Elliott Trott
Evan Gross
Duncan Hussey
Joel Kramer
Kaylee Oliva
Amir Mortazavi
Paul Monk
Edmund Folefac
Steven K. Clinton
Ming Yin

e16567Background: ICI/TKI combinations are a new standard of care for the initial treatment (tx) of mRCC. Efficacy and toxicity of such combination regimens beyond the first-line (1L) setting remai...

Keywords:

Tyrosine-kinase inhibitor
Medicine
Combination therapy
Toxicity
initial treatment
Renal cell carcinoma
Cancer research
standard of care
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations